Lineage Cell Current Debt
| BTX Stock | ILS 210.10 6.70 3.09% |
Lineage Cell Therapeutics has over 5.09 Million in debt which may indicate that it relies heavily on debt financing. With a high degree of financial leverage come high-interest payments, which usually reduce Lineage Cell's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Lineage Cell's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Lineage Cell's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Lineage Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Lineage Cell's stakeholders.
For most companies, including Lineage Cell, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Lineage Cell Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Lineage Cell's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Lineage Cell's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Lineage Cell is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Lineage Cell to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Lineage Cell is said to be less leveraged. If creditors hold a majority of Lineage Cell's assets, the Company is said to be highly leveraged.
Lineage |
Lineage Cell Therapeutics Debt to Cash Allocation
Lineage Cell Therapeutics has accumulated 5.09 M in total debt with debt to equity ratio (D/E) of 3.1, implying the company greatly relies on financing operations through barrowing. Lineage Cell Therapeutics has a current ratio of 3.44, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Lineage Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Lineage Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lineage Cell Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lineage to invest in growth at high rates of return. When we think about Lineage Cell's use of debt, we should always consider it together with cash and equity.Lineage Cell Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lineage Cell's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lineage Cell, which in turn will lower the firm's financial flexibility.Understaning Lineage Cell Use of Financial Leverage
Lineage Cell's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Lineage Cell's total debt position, including all outstanding debt obligations, and compares it with Lineage Cell's equity. Financial leverage can amplify the potential profits to Lineage Cell's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Lineage Cell is unable to cover its debt costs.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people. Please read more on our technical analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out the analysis of Lineage Cell Fundamentals Over Time. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.